Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma

Summary

This study is a single arm phase ll trial including 30 patients with T2N2-3M0、T3-4N0-3M0 (lll-V) head and neck squamous cell carcinoma (HNSCC) eligible forresection, who receive neo-adjvuant Cadonilimab combined with cisplatin and Nab.paclitaxel.This proposed study will evaluate the efficacy and safety of preoperativeadministration of Cadonilimab combined with chemotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC) who are about to undergo surgery.

Timeline

Start

2023-07-19

Primary completion

2024-12-31

Completion

2024-12-31

Publications

• Cao F, Li Y, Fang Q, Lin R, Zhao Z, Xu P, Yan H, Zhang X, Jiang K, Zhou J, Chen C, Lu L, Han F, Li Z, Wu D, Liu X. Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial. Clin Cancer Res. 2025 Sep 15;31(18):3876-3885. doi: 10.1158/1078-0432.CCR-25-1445.

Drugs

Indications